ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

15 Health Benefits of Chia Seeds, According to Science

Tangerine Oil: A Citrusy Essential Oil With Well-Rounded Uses

Natural Remedies for the Prevention of Dry Eyes

Magnesium Deficiency Raises Your Risk of Many Chronic Ailments

Resveratrol supplementation improves arterial stiffness in type 2 diabetics

CoQ10's Potential Capabilities for Your Health

How Can Melatonin Benefit You?

Cloves: Boost Your Immune System the Sweet and Spicy Way

8 Chia Seed Recipes

Cinnamon Health Benefits Proven

 
Print Page
Email Article

Efficacy and Safety of Duloxetine [Cymbalta] in Patients with Chronic Low Back Pain - Source: Spine, May 10, 2010

  [ 50 votes ]   [ Discuss This Article ]
By Vladimir Skljarevski, MD, et al. • www.ProHealth.com • May 14, 2010


Study Design: This was a randomized, double-blind, placebo-controlled clinical trial.

Objective: To assess the efficacy and safety of duloxetine in the treatment of chronic low back pain (CLBP).

Summary of Background Data: Imbalance of serotonin and norepinephrine within modulatory pain pathways has been implicated in the development and maintenance of chronic pain. Duloxetine, a selective reuptake inhibitor of serotonin and norepinephrine, has demonstrated clinical efficacy in 3 distinct chronic pain conditions: diabetic peripheral neuropathic pain, fibromyalgia, and chronic pain because of osteoarthritis.

Methods: In this randomized double-blind trial, adult nondepressed patients with a non-neuropathic CLBP and a weekly mean of the 24-hour average pain score 4 or more at baseline (0-10 scale) were treated with either duloxetine or placebo for 13 weeks. The dose of duloxetine during first 7 weeks was 60 mg once daily.

At week 7, patients reporting less than 30% pain reduction had their dose increased to 120 mg.

The primary outcome measure was the Brief Pain Inventory (BPI) 24-hour average pain rating. Secondary measures included Roland-Morris Disability Questionnaire-24; Patient's Global Impressions of Improvement; Clinical Global Impressions-Severity (CGI-S); BPI-Severity and-Interference (BPI-I); and weekly means of the 24-hour average pain, night pain, and worst pain scores from patient diaries. Quality-of-life, safety, and tolerability outcomes were also assessed.

Results: Compared with placebo-treated patients (least-squares mean change of -1.50), patients on duloxetine (least-squares mean change of -2.32) had a significantly greater reduction in the BPI 24-hour average pain from baseline to endpoint (P = 0.004 at week 13).

Additionally, the duloxetine group significantly improved on Patient's Global Impressions of Improvement; Roland-Morris Disability Questionnaire-24; BPI-Severity and average BPI-Interference; weekly mean of the 24-hour average pain, night pain, and worst pain. Significantly more patients in the duloxetine group (13.9%) compared with placebo (5.8%) discontinued because of adverse events (P = 0.047).

The most common treatment-emergent adverse events in the duloxetine group included nausea, dry mouth, fatigue, diarrhea, hyperhidrosis, dizziness, and constipation.

Conclusion: Duloxetine significantly reduced pain and improved functioning in patients with chronic low back pain. The safety and tolerability were similar to those reported in earlier studies.

Source: Spine, May 10, 2010. PMID: 20424897, by Skljarevski V, Desaiah D, Liu-Seifert H, Zhang Q, Chappell AS, Detke MJ, Iyengar S, Atkinson JH, Backonja M. Lilly Research Laboratories, Indianapolis, Indiana; Medavante Corporation, Hamilton, New Jersey; McLean Hospital & Harvard Medical School, Boston, Massachusetts; Indiana University School of Medicine, Indiana; University of California San Diego Department of Psychiatry, La Jolla, California; University of Wisconsin Medical School, Department of Neurology, Madison.





Post a Comment

Featured Products From the ProHealth Store
Energy NADH™ 12.5mg Ultra EPA  - Fish Oil Optimized Curcumin Longvida®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health

Natural Remedies

Dreaming of a Good Night's Sleep? Dreaming of a Good Night's Sleep?
More Weight Loss than Any Other Discovery in Supplement History More Weight Loss than Any Other Discovery in Supplement History
Natural Bladder Control, Go Less and Live More Natural Bladder Control, Go Less and Live More
Sleep Like a Baby in Nature's Cradle Sleep Like a Baby in Nature's Cradle
"It's Not Easy Being Green" - But It Is Healthy

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map